| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:20465369 | IVR | 1 mg/kg/day | - | No significant effects observed | - |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Increased serotonin (5-HT) levels | Neurological endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Increase in corticosterone levels | Neurological endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Increased serotonin (5-HT) levels | Neurological endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Increase in corticosterone levels | Neurological endocrine-mediated perturbations | |
| PMID:2675279 | IVR | 0.5 % | 0.5 % | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations |
| IVR | 0.5 % | 0.5 % | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 4 % | 4 % | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 4 % | 4 % | Increase in T3 levels | Metabolic endocrine-mediated perturbations | |
| PMID:2824305 | IVR | 0.1 % | - | No significant effects observed | - |
| IVR | 0.5 % | 0.5 % | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 1 % | 1 % | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 1 % | 1 % | Hyperplasia in thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 4 % | 4 % | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 4 % | 4 % | Hyperplasia in thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 4 % | 4 % | Decreased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
| PMID:824186 | IVR | 750 mg/kg | 750 mg/kg | Changes in haemocrit values | Immunological endocrine-mediated perturbations |
| IVR | 750 mg/kg | 750 mg/kg | Adenocarcinoma | Endocrine-mediated cancer;Metabolic endocrine-mediated perturbations | |
| IVR | 750 mg/kg | 750 mg/kg | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 900 mg/kg | 900 mg/kg | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 900 mg/kg | 900 mg/kg | Changes in haemocrit values | Immunological endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Granulosa cell carcinoma | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| PMID:9061850 | IVR | 4 % | 4 % | Hyperplasia in thyroid gland | Metabolic endocrine-mediated perturbations |
| IVR | 4 % | 4 % | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 4 % | 4 % | Thyroid gland carcinoma | Endocrine-mediated cancer;Metabolic endocrine-mediated perturbations | |
| IVR | 4 % | 4 % | Increase in TSH levels | Metabolic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.